Eradication strategy for persistent methicillin-resistant Staphylococcus aureus infection in individuals with cystic fibrosis—the PMEP trial: study protocol for a randomized controlled trial

详细信息    查看全文

• 作者：Mark T Jennings ; Michael P Boyle ; David Weaver ; Karen A Callahan…
• 关键词：Cystic fibrosis ; MRSA ; Randomized controlled trial ; Vancomycin
• 刊名：Trials
• 出版年：2014
• 出版时间：December 2014
• 年：2014
• 卷：15
• 期：1
• 全文大小：283 KB
• 参考文献：1. Boyle, MP (2007) Adult cystic fibrosis. JAMA 298: pp. 1787-1793 ma.298.15.1787" target="_blank" title="It opens in new window">CrossRef
  Cystic Fibrosis Foundation Patient Registry, 2012 Annual Data Report. Cystic Fibrosis Foundation, Bethesda, MD
  2. Dasenbrook, EC, Merlo, CA, Diener-West, M, Lechtzin, N, Boyle, MP (2008) Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 178: pp. 814-821 m.200802-327OC" target="_blank" title="It opens in new window">CrossRef
  3. Dasenbrook, EC, Checkley, W, Merlo, CA, Konstan, MW, Lechtzin, N, Boyle, MP (2010) Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 303: pp. 2386-2392 ma.2010.791" target="_blank" title="It opens in new window">CrossRef
  4. Sanders, DB, Bittner, RC, Rosenfeld, M, Hoffman, LR, Redding, GJ, Goss, CH (2010) Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 182: pp. 627-632 m.200909-1421OC" target="_blank" title="It opens in new window">CrossRef
  5. Garske, LA, Kidd, TJ, Gan, R, Bunting, JP, Franks, CA, Coulter, C, Masel, PJ, Bell, SC (2004) Rifampicin and sodium fusidate reduces the frequency of methicillin-resistant Staphylococcus aureus (MRSA) isolation in adults with cystic fibrosis and chronic MRSA infection. J Hosp Infect 56: pp. 208-214 CrossRef
  6. Macfarlane, M, Leavy, A, McCaughan, J, Fair, R, Reid, AJ (2007) Successful decolonization of methicillin-resistant Staphylococcus aureus in paediatric patients with cystic fibrosis (CF) using a three-step protocol. J Hosp Infect 65: pp. 231-236 CrossRef
  7. Solis, A, Brown, D, Hughes, J, Van Saene, HK, Heaf, DP (2003) Methicillin-resistant Staphylococcus aureus in children with cystic fibrosis: an eradication protocol. Pediatr Pulmonol 36: pp. 189-195 CrossRef
  8. Doe, SJ, McSorley, A, Isalska, B, Kearns, AM, Bright-Thomas, R, Brennan, AL, Webb, AK, Jones, AM (2010) Patient segregation and aggressive antibiotic eradication therapy can control methicillin-resistant Staphylococcus aureus at large cystic fibrosis centres. J Cyst Fibros 9: pp. 104-109 CrossRef
  9. Generali, J, Cada, D (2004) Vancomycin: aerosolization. Hosp Pharm 39: pp. 638-647
  10. Shirai, M, Ide, K, Sato, M (1995) Effect of inhaled vancomycin hydrochloride on elimination of methicillin-resistant Staphylococcus aureus. Nihon Kyobu Shikkan Gakkai Zasshi 33: pp. 1233
  11. Jennings, M, Bucur, C, Boyle, MP, Konstan, M, Dasenbrook, EC (2012) Poster session abstracts: safety and pharmacokinetics of inhaled vancomycin in individuals with cystic fibrosis. Pediatr Pulmonol 47: pp. 223-446 CrossRef
  12. Smyth, AR, Walters, S (2012) Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev.
  
• 刊物主题：Medicine/Public Health, general; Biomedicine general; Statistics for Life Sciences, Medicine, Health Sciences;
• 出版者：BioMed Central
• ISSN：1745-6215

文摘

Background The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) respiratory infection in cystic fibrosis (CF) has increased dramatically over the last decade, and is now affecting approximately 25% of patients. Epidemiologic evidence suggests that persistent infection with MRSA results in an increased rate of decline in FEV1 and shortened survival. Currently, there are no conclusive studies demonstrating an effective and safe treatment protocol for persistent MRSA respiratory infection in CF. Methods/Design The primary objective of this study is to evaluate the safety and efficacy of a 28-day course of vancomycin for inhalation in combination with oral antibiotics in eliminating MRSA from the respiratory tract of individuals with CF and persistent MRSA infection. This is a two-center, randomized, double-blind, comparator-controlled, parallel-group study with 1:1 assignment to either vancomycin for inhalation (250?mg twice a day) or taste-matched placebo for 28?days in individuals with cystic fibrosis. In addition, both groups will receive oral rifampin, a second oral antibiotic -trimethoprim/sulfamethoxazole (TMP/SMX) or doxycycline, protocol determined -mupirocin intranasal cream, and chlorhexidine body washes. Forty patients with persistent respiratory tract MRSA infection will be enrolled: 20 will be randomized to vancomycin for inhalation and 20 to a taste-matched placebo. The primary outcome will be the presence of MRSA in sputum respiratory tract cultures 1?month after the conclusion of treatment. Secondary outcomes include the efficacy of the intervention on: FEV1% predicted, patient reported outcomes, pulmonary exacerbations, and MRSA colony-forming units found in respiratory tract sample culture. Discussion Results of this study will provide guidance to clinicians regarding the safety and effectiveness of a targeted eradication strategy for persistent MRSA infection in CF. Trial registration This trial is registered at ClinicalTrials.gov (NCT01594827, received 05/07/2012) and is funded by the Cystic Fibrosis Foundation (Grants: PMEP10K1 and PMEP11K1).